Literature DB >> 32621957

Metformin preferentially provides neuroprotection following cardiac ischemia/reperfusion in non-diabetic rats.

Juthipong Benjanuwattra1, Nattayaporn Apaijai1, Titikorn Chunchai1, Sasiwan Kerdphoo1, Thidarat Jaiwongkam1, Bussarin Arunsak1, Supawit Wongsuchai1, Nipon Chattipakorn2, Siriporn C Chattipakorn3.   

Abstract

Following acute myocardial infarction, re-establishment of coronary perfusion aggravates further injuries in the heart and remote organs including the brain as a consequence of ischemia/reperfusion (I/R) injury. Since pretreatment with metformin attenuated both cardiac and cerebral I/R injury via AMP-activated protein kinase (AMPK) pathways, we hypothesized that metformin given after ischemia mitigates both cardiac and brain pathologies following cardiac I/R. Male Wistar rats were subjected to either cardiac I/R (30 min-ischemia/120 min-reperfusion; n = 30) or sham operation (n = 5). Metformin 200 mg/kg was given intravenously to the cardiac I/R group (n = 10/group), either during ischemia (D-MET) or at the onset of reperfusion (R-MET). Left ventricular ejection fraction (LVEF) and arrhythmia scores were determined. The heart and brain tissues were collected to determine the extent of injury, mitochondrial function, and apoptosis. Additionally, microglial morphology, Alzheimer's proteins, and dendritic spine density were determined in the brain. Cardiac I/R led to not only reduced LVEF, cardiac mitochondrial dysfunction, and arrhythmias, but also brain mitochondrial dysfunction, apoptosis, Alzheimer's protein aggregation, microglial activation, and dendritic spine loss. A single dose of metformin did not alter p-AMPK/AMPK in both organs. In the heart, impaired LVEF, arrhythmias, infarct size expansion, mitochondrial dysfunction, and apoptosis were not alleviated. On the contrary, metformin attenuated brain mitochondrial dysfunction, apoptosis, and Alzheimer's protein levels. Microglial morphology and dendritic spine density were additionally preserved in D-MET group. In conclusion, metformin given during ischemia preferentially provides neuroprotection against brain mitochondrial dysfunction, apoptosis, microglial activation, and dendritic spine loss in an AMPK-independent manner following cardiac I/R injury.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMPK; Apoptosis; Brain; Cardiac ischemia/reperfusion; Heart; Metformin; Mitochondria

Mesh:

Substances:

Year:  2020        PMID: 32621957     DOI: 10.1016/j.bbadis.2020.165893

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  5 in total

1.  Metformin Alleviates Delayed Hydrocephalus after Intraventricular Hemorrhage by Inhibiting Inflammation and Fibrosis.

Authors:  Yi Cao; Chang Liu; Gaowei Li; Weina Gao; Hui Tang; Shuanmin Fan; Xin Tang; Long Zhao; Haoxiang Wang; Aijun Peng; Chao You; Aiping Tong; Liangxue Zhou
Journal:  Transl Stroke Res       Date:  2022-07-19       Impact factor: 6.800

2.  An apoptosis inhibitor suppresses microglial and astrocytic activation after cardiac ischemia/reperfusion injury.

Authors:  Suchan Liao; Ying Luo; Titikorn Chunchai; Kodchanan Singhanat; Busarin Arunsak; Juthipong Benjanuwattra; Nattayaporn Apaijai; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Inflamm Res       Date:  2022-06-02       Impact factor: 6.986

Review 3.  Cerebral derailment after myocardial infarct: mechanisms and effects of the signaling from the ischemic heart to brain.

Authors:  Paolo Gelosa; Laura Castiglioni; Joanna Rzemieniec; Majeda Muluhie; Marina Camera; Luigi Sironi
Journal:  J Mol Med (Berl)       Date:  2021-10-21       Impact factor: 5.606

4.  Therapeutic potentials of cell death inhibitors in rats with cardiac ischaemia/reperfusion injury.

Authors:  Ying Luo; Nattayaporn Apaijai; Suchan Liao; Chayodom Maneechote; Titikorn Chunchai; Busarin Arunsak; Juthipong Benjanuwattra; Panat Yanpiset; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  J Cell Mol Med       Date:  2022-03-21       Impact factor: 5.310

5.  Metformin use is associated with low risk of case fatality and disability rates in first-ever stroke patients with type 2 diabetes.

Authors:  Wen-Jun Tu; Zheng Liu; Bao-Hua Chao; Feng Yan; Lin Ma; Lei Cao; Xun-Ming Ji; Long-De Wang
Journal:  Ther Adv Chronic Dis       Date:  2022-04-19       Impact factor: 4.970

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.